Why the study?
Osteogenesis imperfecta affects the cardiovascular system, but there is no consensus on how cardiovascular disease in osteogenesis imperfecta should be assessed or managed.
This consensus statement provides the first structured clinical recommendations for the evaluation and management of cardiovascular disease in adults with osteogenesis imperfecta, emphasizing standard symptom-driven cardiovascular assessment and specialized multidisciplinary care for valvular and surgical interventions.
May warrant cardiovascular evaluation in adults with OI; leaves open optimal screening and management protocols.
Osteogenesis imperfecta (OI) is a multisystem disorder most often caused by pathogenic variants in genes that encode type I collagen. Type I collagen is abundant not only in bone but also in multiple tissues including skin, tendons, cornea, blood vessels, and heart. Thus, OI can be expected to affect cardiovascular system, and there are numerous reports of cardiovascular disease (CVD) in people with OI. However, there is no consensus on how CVD in OI should be assessed or managed. To fill this gap, a multidisciplinary group was convened to develop clinical guidance. The work included a systematic review of the available literature and, using a modified Delphi approach, the development of a series of statements summarizing current knowledge. Fourteen clinical recommendations were developed to guide clinicians, patients, and stakeholders about an approach for CVD in adults with OI. This paper describes how the work was conducted and provides the background and rationale for each recommendation. Furthermore, we highlight knowledge gaps and suggest research priorities for the future study of CVD in OI.
No takes yet. Share an insight, caveat, or question.
Folkestad et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: